- First in the life sciences industry to aggregate all interactive advisory board data and deliver AI-powered analytics on trends, themes and topics that matter
- A virtual engagement platform designed to deliver the simplest user experiences with customizable workflows to drive stakeholder engagement and improve insight generation
- The platform is accessible through a web portal and through a mobile application, accessible anytime and anywhere
LONDON, April 19, 2022 (GLOBE NEWSWIRE) — The Virtual Science AI team is committed to helping improve the pharmaceutical industry’s engagement with its stakeholders, as the company launches Virtual Advisory AI. The virtual engagement platform offers a wide range of features, including synchronous and asynchronous interaction, co-collaboration tools, and AI reporting capability.
CEO of Virtual Science AI
“As life science teams embrace hybrid working, it’s an exciting time for virtual work solution providers to partner with teams to shape the ways of working with healthcare stakeholders for the better. , we believe that Virtual Science AI has built the next-generation virtual engagement solutions that will move the needle on advisory board stakeholder experiences and information management, Virtual Science AI is capable of making sense of interactive data in a way that simply hasn’t been done before.”
“Asynchronous engagement allows advisory board participants to provide information in virtual work environments at a time that suits their schedules. It allows participants to engage asynchronously around their schedule over, say, a 2-week period, rather than a predefined 6-hour intensive advisory board, this evolved approach results in a level of engagement higher and better quality in-depth work results..”
The advisory board decision-making process for any organization, regardless of sector, is often time-consuming and requires extensive deliberation and consultation. However, Virtual Science AI strives to help Life Science customers improve the process, so that it is more transparent and faster without compromising the quality of the decision or outcome. The recently launched product will leverage Virtual Science AI’s virtual engagement and insights platform to enable the use of real-time and time-asynchronous engagement strategies to drive participant engagement and improve insights generation, leading to the generation of AI-powered insights reports on important trends, themes and topics relevant to life science teams.
The solution will equip life science industry stakeholders for compliant interactions with healthcare professionals, patient communities and decision makers in a barrier-free virtual environment while improving strategic decisions. Virtual Advisory AI, a software-as-a-service (SaaS) organization, enhances current virtual advisory board solutions in the industry by providing medical and project manager-led services that leverage the platform’s capabilities to Virtual Science AI to perform unique AI-generated activities and services. analytics reports collected from virtual engagement activities.
For more information on Virtual Advisory AI, visit – www.virtualscienceai.com.
About Virtual Scientific AI
Virtual Science AI is a global provider of virtual advisory services in the pharmaceutical industry. The company uses its virtual platform and AI models to enhance engagement with stakeholders in R&D, medical affairs, public affairs and commercial life sciences functions. The goal is to help shape how life science teams interact with their stakeholders for the better and to use the results of the interaction to improve critical decision making at different stages of the life cycle. life of the product to help bring solutions to patients.
virtual scientific AI
Tom Hughes CEO of Virtual Science AI
United Kingdom, London
+44 (0) 7535599820